Study
N-acetyl Cysteine Shows Limited Long-term Benefits for Bipolar Disorder
N-acetyl cysteine (NAC) treatment did not significantly reduce mood episode recurrence in bipolar disorder patients over a maintenance phase.
Summary
In plain language
This study explored whether N-acetyl cysteine (NAC), a supplement, can help maintain mood stability in people with bipolar disorder. Initially, participants took NAC for eight weeks, showing reduced depression symptoms. Following this, the study compared continued NAC treatment to a placebo for another 24 weeks. Results showed no significant difference in mood episode recurrence or quality of life between the NAC and placebo groups during this period. While NAC helped initially, its long-term benefits as a maintenance treatment were unclear. Seniors interested in using supplements for mood disorders should discuss these findings with their healthcare provider.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
The study was a double-blind, placebo-controlled trial with 149 participants who initially took NAC for eight weeks. Afterward, they were randomly assigned to continue NAC or switch to a placebo for 24 more weeks.
Initial NAC treatment reduced depression scores, but no significant differences were found in mood recurrence between NAC and placebo groups in the maintenance phase.
The study suggests NAC may not offer long-term benefits for mood stability in bipolar disorder beyond initial treatment.
Potential limitations include the study's specific design and participants' continued use of other treatments, which could affect results.
Seniors should talk to their healthcare providers about these findings before considering NAC as part of their treatment plan.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
N-acetyl Cysteine Shows Limited Long-term Benefits for Bipolar Disorder
Published August 2012 · DOI 10.1186/1741-7015-10-91
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored May 10, 2026 using rubric v9_2026-04-08.
Assessment
The study is a high-quality randomized controlled trial with strong methodology, including randomization, blinding, and appropriate statistical analysis. However, it lacks specific relevance to seniors and has not been replicated or externally validated.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 10.0/10 | |
| Bias control | 10.0/10 | |
| Statistical methods | 10.0/10 | |
| Reporting completeness | 10.0/10 | |
| Conflicts & funding | 10.0/10 | |
| Replication | 0.0/10 | |
| Relevance to chosen population | 0.0/10 | |
| Journal Reliability | 10.0/10 |
Additional Notes
The study's findings are robust within its design but may not be directly applicable to older adults without further age-specific analysis.
Treatments Evaluated in This Research
Review the interventions studied here and compare them against the broader treatment library.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.